Meeting
2020 ASCO Virtual Scientific Program
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
Authors
Alexander E. Drilon
Memorial Sloan Kettering Cancer Center, New York, NY
Alexander E. Drilon , Anna F. Farago , Daniel Shao-Weng Tan , Shivaani Kummar , Raymond S. McDermott , Jordan Berlin , Jyoti D. Patel , Marcia S. Brose , Serge Leyvraz , Makoto Tahara , Benjamin Maurice Solomon , John A. Reeves , Marc Mardoche Fellous , Nicoletta Brega , Barrett H. Childs , Ulrik Niels Lassen , David S. Hong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NTC02122913, NCT02576431, NCT02637687
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3610)
DOI
10.1200/JCO.2020.38.15_suppl.3610
Abstract #
3610
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon
Poster
2021 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas